MNKD
MANNKIND CORP
NASDAQ · Healthcare · Biotechnology · US
$3.09
+1.64%Year over year
Reported trailing growth
- Revenue
- +30.5%
- EBITDA
- -61.9%
- EBIT
- -88.4%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +38.6%
- EBITDA
- +220.1%
- EPS
- +120.6%
Three-year CAGR
- Revenue
- +51.8%
- EBITDA
- +29.6%
- EBIT
- +111.5%
- Net income
- -78.7%
- EPS
- -80.0%
- Free cash flow
- -58.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026